ArticleJournal of cancer research and clinical oncology2026
Diagnostic performance and clinical limitations of sentinel lymph node biopsy in head and neck melanoma: a 20-year retrospective cohort study.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSentinel lymph node biopsy (SLNB) is a standard procedure for nodal staging in cutaneous melanoma. However, its diagnostic performance in the head and neck region remains limited due to complex lymphatic drainage patterns. This study aimed to evaluate the long-term diagnostic accuracy of SLNB in head and neck melanoma and to analyze anatomical and clinical factors associated with false-negative results.
methodsThis retrospective single-center cohort study included patients with cutaneous head and neck melanoma who underwent SLNB between 2002 and 2022. Patients were stratified into two cohorts (2002-2011 and 2012-2022). Detection rates, sensitivity, negative predictive value, and false-negative rates were calculated. Overall survival was analyzed using Kaplan-Meier estimates and compared by log-rank testing.
resultsA total of 189 patients were included. Sentinel lymph node detection significantly improved from 78.2% in the earlier cohort to 98.0% in the later cohort (p < 0.0001). Across the combined cohort, SLNB sensitivity was 72.5%, with a false-negative rate of 27.5%. False-negative events predominantly occurred in anatomically complex drainage regions. Sentinel lymph node status was not significantly associated with overall survival (p = 0.627).
conclusionsDespite substantial improvements in detection rates, SLNB in head and neck melanoma demonstrates clinically relevant limitations in diagnostic sensitivity. The observed false-negative rate highlights a risk of understaging, which may affect eligibility for adjuvant systemic therapies. SLNB findings should therefore be interpreted in the context of anatomical risk patterns and integrated into individualized follow-up strategies. The lack of an association between sentinel lymph node status and overall survival may reflect the impact of modern adjuvant systemic therapies and the distinct biological behavior of head and neck melanoma. However, this finding should be interpreted with caution given the limited sample size. These findings underscore the importance of procedural expertise and risk-adapted surveillance in this anatomically complex region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.